Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 21 analyst ratings
Hold
Strong Buy 14%
Buy 33%
Hold 38%
Sell 14%
Strong Sell 0%

Bulls say

ResMed has demonstrated strong financial performance with an operating margin increase of 80 basis points year-over-year, largely attributed to a 230 basis point gross margin expansion driven by pricing strategies, manufacturing efficiencies, and reduced component costs. The company reported respiratory sales growth of 12% in the Americas, amounting to $749 million, surpassing the 8% growth seen in the rest of the world, which posted respiratory sales of $377 million. Additionally, with the anticipated growth in wearables and the positive outlook on CPAP patient numbers, ResMed is expected to see significant improvements in both gross and operating margins as its supply chain stabilizes and its product mix shifts towards masks and accessories.

Bears say

ResMed's financial outlook is hindered by several structural challenges, including stagnant gross margins and anticipated revenue growth falling below 5% due to potential market share losses exacerbated by competitive pressures and the impact of GLP-1 weight loss drugs. Despite a slight earnings beat in F2Q25, organic revenue growth decelerated from 11% to 10%, which may indicate a trend towards slower growth amidst increasing market competition. Additionally, the company has lowered positive impact estimates from GLP-1s on CPAP patients, suggesting potential headwinds that could further depress future earnings estimates for FY26 and FY27, with the FY27 earnings per share estimate now positioned at a street-low level.

ResMed (RMD) has been analyzed by 21 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 33% recommend Buy, 38% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 21 analysts, ResMed (RMD) has a Hold consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $178.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $178.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.